參考文獻 |
Reference
1. Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control. 1997;8(3):346–55.
2. Wang L-F. Mutagenicity and aromatic amine content of fumes from heated cooking oils produced in Taiwan. Food Chem Toxicol. 1999;37(2–3):125–34.
3. Makena PS, Chung K-T. Evidence that 4‐aminobiphenyl, benzidine, and benzidine congeners produce genotoxicity through reactive oxygen species. Environ Mol Mutagen. 2007;48(5):404–13.
4. Torino JL, Burger MS, Reznikoff CA, Swaminathan S. Role of TP53 in repair of N-(deoxyguanosin-8-yl)-4-aminobiphenyl adducts in human transitional cell carcinoma of the urinary bladder. Carcinogenesis. 2001;22(1):147–54.
5. Murata M, Kawanishi S. Mechanisms of oxidative DNA damage induced by carcinogenic arylamines. Front Biosci J Virt Lib. 2011;16:1132–43.
6. David BA. The health consequences of smoking—50 years of progress. A Report of the Surgeon General. 2014.
7. Wang L-Y, Chen C-J, Zhang Y-J, Tsai W-Y, Lee P-H, Feitelson MA, et al. 4-Aminobiphenyl DNA damage in liver tissue of hepatocellular carcinoma patients and controls. Am J Epidemiol. 1998;147(3):315–23.
8. Penning TM. Metabolic activation of chemical carcinogens. Chemical Carcinogenesis. 2011; p. 135–158.
9. Moonen HJ, Briedé JJ, van Maanen JM, Kleinjans JC, de Kok TM. Generation of free radicals and induction of DNA adducts by activation of heterocyclic aromatic amines via different metabolic pathways in vitro. Mol Carcinog. 2002;35(4):196–203.
10. Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health Part B. 2009;12(5–6):440–72.
11. Turesky RJ, Le Marchand L. Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines. Chem Res Toxicol. 2011;24(8):1169–214.
12. Schut HA, Snyderwine EG. DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. Carcinogenesis. 1999;20(3):353–68.
13. Baird WM, Hooven LA, Mahadevan B. Carcinogenic polycyclic aromatic hydrocarbon‐DNA adducts and mechanism of action. Environ Mol Mutagen. 2005;45(2‐3):106–14.
14. Gupta PK. Fundamentals of toxicology: essential concepts and applications. Academic Press. 2016.
15. Cimino MC. Comparative overview of current international strategies and guidelines for genetic toxicology testing for regulatory purposes. Environ Mol Mutagen. 2006;47(5):362–90.
16. Jena GB, Kaul CL, Ramarao P. Genotoxicity testing, a regulatory requirement for drug discovery and development: impact of ICH guidelines. Indian J Pharmacol. 2002;34(2):86–99.
17. Heinonen T, Louekari K, Tähti H. Need for harmonized strategies and improved assessment of carcinogenic and genotoxic potencies of chemical substances. J Transl Toxicol. 2014;1(1):76–87.
18. Nesslany F. The current limitations of in vitro genotoxicity testing and their relevance to the in vivo situation. Food Chem Toxicol. 2017;106:609–15.
19. Corvi R, Madia F. In vitro genotoxicity testing–Can the performance be enhanced? Food Chem Toxicol. 2017;106:600–8.
20. Ehrlich V, Darroudi F, Uhl M, Steinkellner H, Gann M, Majer BJ, et al. Genotoxic effects of ochratoxin A in human-derived hepatoma (HepG2) cells. Food Chem Toxicol. 2002;40(8):1085–90.
21. Knasmüller S, Mersch-Sundermann V, Kevekordes S, Darroudi F, Huber WW, Hoelzl C, et al. Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge. Toxicology. 2004;198(1–3):315–28.
22. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis. 2000;21(3):361–70.
23. Burger MS, Torino JL, Swaminathan S. DNA damage in human transitional cell carcinoma cells after exposure to the proximate metabolite of the bladder carcinogen 4‐aminobiphenyl. Environ Mol Mutagen. 2001;38(1):1–11.
24. Chen T. The role of MicroRNA in chemical carcinogenesis. J Environ Sci Health Part C. 2010;28(2):89–124.
25. Wang SC, Chung J-G, Chen C-H, Chen S-C. 2-and 4-Aminobiphenyls induce oxidative DNA damage in human hepatoma (HepG2) cells via different mechanisms. Mutat Res Mol Mech Mutagen. 2006;593(1–2):9–21.
26. Lin C-H, Wu J-C, Chiou B-H, Chen C-H, Ma N, Chang CY, et al. MicroRNA regulation of DNA repair gene expression in 4-aminobiphenyl-treated HepG2 cells. Toxicology. 2014;322:69–77.
27. Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of’conditional haploinsufficiency’. Cell Cycle. 2007;6(19):2344–7.
28. Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer. 2016;16(1):20.
29. Patil P, Patil K, Hande S, Pawar V, Mujumdar A, Mhatre A. Conceptual study of Dooshivisha (Cumulative toxicity) wrt Ancient classics and Modern science. J Ayurveda Integr Med. 2016;1(3):144–50.
30. Ambs S, Neumann H-G. Acute and chronic toxicity of aromatic amines studied in the isolated perfused rat liver. Toxicol Appl Pharmacol. 1996;139(1):186–94.
31. Larcher T, Perrichon P, Vignet C, Ledevin M, Le Menach K, Lyphout L, et al. Chronic dietary exposure of zebrafish to PAH mixtures results in carcinogenic but not genotoxic effects. Environ Sci Pollut Res. 2014;21(24):13833–49.
32. Wang S, Sugamori KS, Tung A, McPherson JP, Grant DM. N-hydroxylation of 4-aminobiphenyl by CYP2E1 produces oxidative stress in a mouse model of chemically induced liver cancer. Toxicol Sci. 2015;144(2):393–405.
33. Yu MC, Skipper PL, Taghizadeh K, Tannenbaum SR, Chan KK, Henderson BE, et al. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. JNCI J Natl Cancer Inst. 1994;86(9):712–6.
34. Ross RK, Jones PA, Yu MC. Bladder cancer epidemiology and pathogenesis. In seminars in oncology. 1996; p. 536.
35. Mimi CY, Skipper PL, Tannenbaum SR, Chan KK, Ross RK. Arylamine exposures and bladder cancer risk. Mutat Res Mol Mech Mutagen. 2002;506:21–8.
36. Chen S-Y, Wang L-Y, Lunn RM, Tsai W-Y, Lee P-H, Lee C-S, et al. Polycyclic aromatic hydrocarbon‐DNA adducts in liver tissues of hepatocellular carcinoma patients and controls. Int J Cancer. 2002;99(1):14–21.
37. Lee Y-CA, Cohet C, Yang Y-C, Stayner L, Hashibe M, Straif K. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol. 2009;38(6):1497–511.
38. D’Autréaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol. 2007;8(10):813–24.
39. Amer J, Ghoti H, Rachmilewitz E, Koren A, Levin C, Fibach E. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol. 2006;132(1):108–13.
40. Bardaweel SK, Gul M, Alzweiri M, Ishaqat A, ALSalamat HA, Bashatwah RM. Reactive oxygen species: the dual role in physiological and pathological conditions of the human body. Eurasian J Med. 2018;50(3):193.
41. Hall EJ, Rossi HH, Kellerer AM, Goodman L, Marino S. Radiobiological studies with monoenergetic neutrons. Radiat Res. 1973;54(3):431–43.
42. Salehi F, Behboudi H, Kavoosi G, Ardestani SK. Oxidative DNA damage induced by ROS-modulating agents with the ability to target DNA: A comparison of the biological characteristics of citrus pectin and apple pectin. Sci Rep. 2018;8(1):1–16.
43. Shokolenko I, Venediktova N, Bochkareva A, Wilson GL, Alexeyev MF. Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids Res. 2009;37(8):2539–48.
44. Bravard A, Vacher M, Gouget B, Coutant A, de Boisferon FH, Marsin S, et al. Redox regulation of human OGG1 activity in response to cellular oxidative stress. Mol Cell Biol. 2006;26(20):7430–6.
45. Lee BWL, Ghode P, Ong DST. Redox regulation of cell state and fate. Redox Biol. 2019;25:101056.
46. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4(3):143–59.
47. Wan G, Mathur R, Hu X, Zhang X, Lu X. miRNA response to DNA damage. Trends Biochem Sci. 2011;36(9):478–84.
48. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294(5543):853–8.
49. Kim Y-K, Kim VN. Processing of intronic microRNAs. EMBO J. 2007;26(3):775–83.
50. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.
51. Wan G, Liu Y, Han C, Zhang X, Lu X. Noncoding RNAs in DNA repair and genome integrity. Antioxid Redox Signal. 2014;20(4):655–77.
52. Gooderham NJ, Koufaris C. Using microRNA profiles to predict and evaluate hepatic carcinogenic potential. Toxicol Lett. 2014;228(2):127–32.
53. Han C, Wan G, Langley RR, Zhang X, Lu X. Crosstalk between the DNA damage response pathway and microRNAs. Cell Mol Life Sci. 2012;69(17):2895–906.
54. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res. 2009;69(3):1221–9.
55. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011;41(2):210–20.
56. Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci. 2010;107(15):6982–7.
57. Lin Y, Liu X, Cheng Y, Yang J, Huo Y, Zhang C. Involvement of MicroRNAs in hydrogen peroxide-mediated gene regulation and cellular injury response in vascular smooth muscle cells. J Biol Chem. 2009;284(12):7903–13.
58. Lin J, Chuang C-C, Zuo L. Potential roles of microRNAs and ROS in colorectal cancer: diagnostic biomarkers and therapeutic targets. Oncotarget. 2017;8(10):17328.
59. He J, Jiang B-H. Interplay between reactive oxygen species and microRNAs in cancer. Curr Pharmacol Rep. 2016;2(2):82–90.
60. Kwon J-E, Kim B-Y, Kwak S-Y, Bae I-H, Han Y-H. Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1. Apoptosis. 2013;18(7):896–909.
61. Lizarraga D, Gaj S, Brauers KJ, Timmermans L, Kleinjans JC, van Delft JH. Benzo [a] pyrene-induced changes in MicroRNA–mRNA networks. Chem Res Toxicol. 2012;25(4):838–49.
62. Perrone S, Lotti F, Geronzi U, Guidoni E, Longini M, Buonocore G. Oxidative stress in cancer-prone genetic diseases in pediatric age: the role of mitochondrial dysfunction. Oxid Med Cell Longev. 2016
63. Hammons GJ, Milton D, Stepps K, Guengerich FP, Tukey RH, Kadlubar FF. Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes. Carcinogenesis. 1997;18(4):851–4.
64. Shibutani S, Suzuki N, Tan X, Johnson F, Grollman AP. Influence of flanking sequence context on the mutagenicity of acetylaminofluorene-derived DNA adducts in mammalian cells. Biochemistry. 2001;40(12):3717–22.
65. Mu H, Kropachev K, Wang L, Zhang L, Kolbanovskiy A, Kolbanovskiy M, et al. Nucleotide excision repair of 2-acetylaminofluorene-and 2-aminofluorene-(C8)-guanine adducts: molecular dynamics simulations elucidate how lesion structure and base sequence context impact repair efficiencies. Nucleic Acids Res. 2012;40(19):9675–90.
66. Giglia-Mari G, Zotter A, Vermeulen W. DNA damage response. Cold Spring Harb Perspect Biol. 2011;3(1):a000745.
67. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007;28(5):739–45.
68. Podhorecka M, Skladanowski A, Bozko P. H2AX phosphorylation: its role in DNA damage response and cancer therapy. J Nucleic Acids. 2010.
69. Weber S. Light-driven enzymatic catalysis of DNA repair: a review of recent biophysical studies on photolyase. Biochim Biophys Acta BBA-Bioenerg. 2005;1707(1):1–23.
70. Pegg AE. Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. Chem Res Toxicol. 2011;24(5):618–39.
71. Mao Z, Bozzella M, Seluanov A, Gorbunova V. DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle. 2008;7(18):2902–6.
72. Weterings E, Van Gent DC. The mechanism of non-homologous end-joining: a synopsis of synapsis. DNA Repair. 2004;3(11):1425–35.
73. Rodgers K, McVey M. Error‐prone repair of DNA double‐strand breaks. J Cell Physiol. 2016;231(1):15–24.
74. Zhang J. The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy. Cell Biosci. 2013;3(1):11.
75. Li X, Heyer W-D. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008 Jan;18(1):99–113.
76. Bhatti S, Kozlov S, Farooqi AA, Naqi A, Lavin M, Khanna KK. ATM protein kinase: the linchpin of cellular defenses to stress. Cell Mol Life Sci. 2011;68(18):2977.
77. Altmeyer M, Lukas J. To spread or not to spread—chromatin modifications in response to DNA damage. Curr Opin Genet Dev. 2013;23(2):156–65.
78. Chapman JR, Taylor MR, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell. 2012;47(4):497–510.
79. Nimonkar AV, Genschel J, Kinoshita E, Polaczek P, Campbell JL, Wyman C, et al. BLM–DNA2–RPA–MRN and EXO1–BLM–RPA–MRN constitute two DNA end resection machineries for human DNA break repair. Genes Dev. 2011;25(4):350–62.
80. Zhao W, Vaithiyalingam S, San Filippo J, Maranon DG, Jimenez-Sainz J, Fontenay GV, et al. Promotion of BRCA2-dependent homologous recombination by DSS1 via RPA targeting and DNA mimicry. Mol Cell. 2015;59(2):176–87.
81. Holloman WK. Unraveling the mechanism of BRCA2 in homologous recombination. Nat Struct Mol Biol. 2011;18(7):748.
82. Sebesta M, Burkovics P, Juhasz S, Zhang S, Szabo JE, Lee MY, et al. Role of PCNA and TLS polymerases in D-loop extension during homologous recombination in humans. DNA Repair. 2013;12(9):691–8.
83. Ashcroft M, Kubbutat MH, Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol. 1999;19(3):1751–8.
84. Helton ES, Chen X. p53 modulation of the DNA damage response. J Cell Biochem. 2007;100(4):883–96.
85. Pellegata NS, Antoniono RJ, Redpath JL, Stanbridge EJ. DNA damage and p53-mediated cell cycle arrest: a reevaluation. Proc Natl Acad Sci. 1996;93(26):15209–14.
86. Chen J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med. 2016;6(3):a026104.
87. Williams AB, Schumacher B. p53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med. 2016;6(5):a026070.
88. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis-the p53 network. J Cell Sci. 2003;116(20):4077–85.
89. Liu Y, Qiang W, Xu X, Dong R, Karst AM, Liu Z, et al. Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells. Oncotarget. 2015;6(36):38983.
90. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR‐200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9(6):582–9.
91. Natsume T, Nishimura K, Minocherhomji S, Bhowmick R, Hickson ID, Kanemaki MT. Acute inactivation of the replicative helicase in human cells triggers MCM8–9-dependent DNA synthesis. Genes Dev. 2017;31(8):816–29.
92. Park J, Long DT, Lee KY, Abbas T, Shibata E, Negishi M, et al. The MCM8-MCM9 Complex Promotes RAD51 Recruitment at DNA Damage Sites To Facilitate Homologous Recombination. Mol Cell Biol. 201;33(8):1632–44.
93. Lutzmann M, Grey C, Traver S, Ganier O, Maya-Mendoza A, Ranisavljevic N, et al. MCM8- and MCM9-Deficient Mice Reveal Gametogenesis Defects and Genome Instability Due to Impaired Homologous Recombination. Mol Cell. 2012;47(4):523–34.
94. Lutzmann M, Bernex F, de Jesus C da C, Hodroj D, Marty C, Plo I, et al. MCM8-and MCM9 deficiencies cause lifelong increased hematopoietic DNA damage driving p53-dependent myeloid tumors. Cell Rep. 2019;28(11):2851-2865. e4.
95. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5):S5–16.
96. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
97. Lee J-S, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology. 2004;127(5):S51–5.
98. Duan M, Hao J, Cui S, Worthley DL, Zhang S, Wang Z, et al. Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. Cell Res. 2018;28(3):359–73.
99. Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13(2):125–37.
100. Zhang Y-J. Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma. World J Hepatol. 2010;2(3):94–102.
101. SUGIMURA T, NAGAO M, WAKABAYASHI K. How we should deal with unavoidable exposure of man to environmental mutagens : cooked food mutagen discovery, facts and lessons for cancer prevention. We Should Deal Unavoidable Expo Man Environ Mutagens Cooked Food Mutagen Discov Facts Lessons Cancer Prev. 2000;447(1):15–25.
102. Turesky RJ. Heterocyclic Aromatic Amine Metabolism, Dna Adduct Formation, Mutagenesis, and Carcinogenesis. Drug Metab Rev. 2002;34(3):625–50.
103. Autrup H. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res Toxicol Environ. 2000;464(1):65–76.
104. Pluchino LA, Liu AK-Y, Wang H-CR. Reactive oxygen species-mediated breast cell carcinogenesis enhanced by multiple carcinogens and intervened by dietary ergosterol and mimosine. Free Radic Biol Med. 2015;80:12–26.
105. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996;313(1):17–29.
106. Chiba T, Marusawa H, Ushijima T. Inflammation-Associated Cancer Development in Digestive Organs: Mechanisms and Roles for Genetic and Epigenetic Modulation. Gastroenterology. 2012;143(3):550–63.
107. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011;9(1):171.
108. Wang Z, Li Z, Ye Y, Xie L, Li W. Oxidative Stress and Liver Cancer: Etiology and Therapeutic Targets. Oxid Med Cell Longev. 2016.
109. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, et al. c-Myc Can Induce DNA Damage, Increase Reactive Oxygen Species, and Mitigate p53 Function: A Mechanism for Oncogene-Induced Genetic Instability. Mol Cell. 2002;9(5):1031–44.
110. Hanczko R, Fernandez DR, Doherty E, Qian Y, Vas G, Niland B, et al. Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest. 2009;119(6):1546–57.
111. Majumder S, Roy S, Kaffenberger T, Wang B, Costinean S, Frankel W, et al. Loss of Metallothionein Predisposes Mice to Diethylnitrosamine-Induced Hepatocarcinogenesis by Activating NF-κB Target Genes. Cancer Res. 2010 Dec 15;70(24):10265–76.
112. Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening. Liver Int. 2018;38:2–6.
113. Garcia GR, Noyes PD, Tanguay RL. Advancements in zebrafish applications for 21st century toxicology. Pharmacol Ther. 2016;161:11–21.
114. Goessling W, Sadler KC. Zebrafish: an important tool for liver disease research. Gastroenterology. 2015;149(6):1361–77.
115. White R, Rose K, Zon L. Zebrafish cancer: the state of the art and the path forward. Nat Rev Cancer. 2013;13(9):624–36.
116. Wilkins BJ, Pack M. Zebrafish models of human liver development and disease. Compr Physiol. 2013;3(3):1213–30.
117. Phillips JB, Westerfield M. Zebrafish models in translational research: tipping the scales toward advancements in human health. Dis Model Mech. 2014;7(7):739–43.
118. Zhang B, Xuan C, Ji Y, Zhang W, Wang D. Zebrafish xenotransplantation as a tool for in vivo cancer study. Fam Cancer. 2015;14(3):487–93.
119. Mirbahai L, Williams TD, Zhan H, Gong Z, Chipman JK. Comprehensive profiling of zebrafish hepatic proximal promoter CpG island methylation and its modification during chemical carcinogenesis. BMC Genomics. 2011;12:3.
120. Basten SG, Davis EE, Gillis AJM, van Rooijen E, Stoop H, Babala N, et al. Mutations in LRRC50 predispose zebrafish and humans to seminomas. PLoS Genet. 2013;9(4):e1003384.
121. Spitsbergen JM, Tsai H-W, Reddy A, Miller T, Arbogast D, Hendricks JD, et al. Neoplasia in Zebrafish (Danio rerio) Treated with N-methyl-N’nitro-N-nitrosoguanidine by Three Exposure Routes at ifferent Developmental Stages. Toxicol Pathol. 2000;28(5):716–25.
122. Nguyen AT, Emelyanov A, Koh CHV, Spitsbergen JM, Lam SH, Mathavan S, et al. A high level of liver-specific expression of oncogenic Kras(V12) drives robust liver tumorigenesis in transgenic zebrafish. Dis Model Mech. 2011;4(6):801–13.
123. Liu W, Chen J-R, Hsu C-H, Li Y-H, Chen Y-M, Lin C-Y, et al. A zebrafish model of intrahepatic cholangiocarcinoma by dual expression of hepatitis B virus X and hepatitis C virus core protein in liver. Hepatology. 2012;56(6):2268–76.
124. Lin H-S, Huang Y-L, Wang Y-RS, Hsiao E, Hsu T-A, Shiao H-Y, et al. Identification of Novel Anti-Liver Cancer Small Molecules with Better Therapeutic Index Than Sorafenib via Zebrafish Drug Screening Platform. Cancers. 2019;11(6):739.
125. Yang W-Y, Rao P-S, Luo Y-C, Lin H-K, Huang S-H, Yang J-M, et al. Omics-based Investigation of Diet-induced Obesity Synergized with HBx, Src, and p53 Mutation Accelerating Hepatocarcinogenesis in Zebrafish Model. Cancers. 2019;11(12):1899.
126. Brown HK, Schiavone K, Tazzyman S, Heymann D, Chico TJ. Zebrafish xenograft models of cancer and metastasis for drug discovery. Expert Opin Drug Discov. 2017;12(4):379–89.
127. Chen L, Groenewoud A, Tulotta C, Zoni E, Kruithof-de Julio M, van der Horst G, et al. Chapter 17 - A zebrafish xenograft model for studying human cancer stem cells in distant metastasis and therapy response. Methods in Cell Biology. Academic Press; 201. p. 471–96.
128. Zhang B, Shimada Y, Kuroyanagi J, Nishimura Y, Umemoto N, Nomoto T, et al. Zebrafish xenotransplantation model for cancer stem-like cell study and high-throughput screening of inhibitors. Tumor Biol. 2014;35(12):11861–9.
129. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci. 1989;86(20):7696–700.
130. Orzechowski A, Schrenk D, Schut HAJ, Bock KW. Consequences of 3-methylcholanthrene-type induction for the metabolism of 4-aminobiphenyl in isolated rat hepatocytes. Carcinogenesis. 1994;15(3):489–94.
131. Lin H-D, Wang F-Z, Lee C-Y, Nien C-Y, Tseng Y-K, Yao C-L, et al. 4-Aminobiphenyl inhibits the DNA homologous recombination repair in human liver cells: The role of miR-630 in downregulating RAD18 and MCM8. Toxicology. 2020;440:152441.
132. Lin H-D, Yao C-L, Ou W-J, Luo Y-H, Chen SC. 4-Aminobiphenyl suppresses homologous recombination repair by a reactive oxygen species-dependent p53/miR-513a-5p/p53 loop. Toxicology. 2020;444:152580.
133. Sie Z-L, Li R-Y, Sampurna BP, Hsu P-J, Liu S-C, Wang H-D, et al. WNK1 Kinase Stimulates Angiogenesis to Promote Tumor Growth and Metastasis. Cancers. 2020;12(3).
134. Mišík M, Nersesyan A, Ropek N, Huber WW, Haslinger E, Knasmueller S. Use of human derived liver cells for the detection of genotoxins in comet assays. Mutat Res Toxicol Environ Mutagen. 2019;845:402995.
135. Di Gennaro A, Damiano V, Brisotto G, Armellin M, Perin T, Zucchetto A, et al. A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness. Cell Death Differ. 2018;25(12):2165–80.
136. Chen Y, Li Z, Dong Z, Beebe J, Yang K, Fu L, et al. 14-3-3σ contributes to radioresistance by regulating DNA repair and cell cycle via PARP1 and CHK2. Mol Cancer Res. 2017;15(4):418–28.
137. Zhang X, Xu R, Zhang C, Xu Y, Han M, Huang B, et al. Trifluoperazine, a novel autophagy inhibitor, increases radiosensitivity in glioblastoma by impairing homologous recombination. J Exp Clin Cancer Res. 2017;36(1):118.
138. Hartford SA, Luo Y, Southard TL, Min IM, Lis JT, Schimenti JC. Minichromosome maintenance helicase paralog MCM9 is dispensible for DNA replication but functions in germ-line stem cells and tumor suppression. Proc Natl Acad Sci. 2011;108(43):17702–7.
139. Yang S, Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett. 2017;13(3):1041–7.
140. Wang Y, Pan T, Li L, Wang H, Zhang D, Yang H. Benzo(a)pyrene promotes Hep-G2 cell migration and invasion by upregulating phosphorylated extracellular signal-regulated kinase expression. Oncol Lett. 2018;15(6):8325–32.
141. Prasad S, Gupta SC, Tyagi AK. Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals. Cancer Lett. 2017;387:95–105.
142. Galadari S, Rahman A, Pallichankandy S, Thayyullathil F. Reactive oxygen species and cancer paradox: To promote or to suppress? Free Radic Biol Med. 2017;104:144–64.
142. Hill D, Chen L, Snaar-Jagalska E, Chaudhry B. Embryonic zebrafish xenograft assay of human cancer metastasis. F1000Research. 2018.
144. Chen H-J, Hu M-H, Xu F-G, Xu H-J, She J-J, Xia H-P. Understanding the inflammation-cancer transformation in the development of primary liver cancer. Hepatoma Res. 2018;4(7):29.
145. Refolo MG, Messa C, Guerra V, Carr BI, D’Alessandro R. Inflammatory Mechanisms of HCC Development. Cancers. 2020;12(3):641.
146. Shi J, Wang X, Lyu L, Jiang H, Zhu H-J. Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes. Drug Metab Pharmacokinet. 2018;33(2):133–40.
147. Lançon A, Hanet N, Jannin B, Delmas D, Heydel J-M, Lizard G, et al. Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab Dispos. 2007;35(5):699–703.
148. Hu X, Yang T, Li C, Zhang L, Li M, Huang W, et al. Human fetal hepatocyte line, L-02, exhibits good liver function in vitro and in an acute liver failure model. In: Transplantation Proceedings. 2013. p. 695–700.
149. Wu Y, Geng X, Wang J, Miao Y, Lu Y, Li B. The HepaRG cell line, a superior in vitro model to L-02, HepG2 and hiHeps cell lines for assessing drug-induced liver injury. Cell Biol Toxicol. 2016;32(1):37–59.
150. LeCluyse EL, Madan A, Hamilton G, Carroll K, DeHaan R, Parkinson A. Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol. 2000;14(4):177–88.
151. Gilot D, Loyer P, Corlu A, Glaise D, Lagadic-Gossmann D, Atfi A, et al. Liver protection from apoptosis requires both blockage of initiator caspase activities and inhibition of ASK1/JNK pathway via glutathione S-transferase regulation. J Biol Chem. 2002;277(51):49220–9.
152. Gerets HHJ, Tilmant K, Gerin B, Chanteux H, Depelchin Bo, Dhalluin S, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012;28(2):69–87.
153. He X, He L, Hannon GJ. The Guardian’s Little Helper: MicroRNAs in the p53 Tumor Suppressor Network. Cancer Res. 2007;67(23):11099–101.
154. Raver-Shapira N, Oren M. Tiny Actors, Great Roles: microRNAs in p53’s Service. Cell Cycle. 2007;6(21):2656–61.
155. Li S, Xu Y-N, Niu X, Li Z, Wang J-F. miR-513a-5p targets Bcl-2 to promote dichlorvos induced apoptosis in HK-2 cells. Biomed Pharmacother. 2018;108:876–82.
156. Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song JS, et al. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell. 2010;38(5):689–99.
157. Luo Z, Cui R, Tili E, Croce C. Friend or Foe: MicroRNAs in the p53 network. Cancer Lett. 2018;419:96–102.
158. Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. Mechanisms of transcriptional regulation by p53. Cell Death Differ. 2018;25(1):133–43.
159. Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol. 2019;20(4):199–210.
160. Huang Y, Chuang A, Hao H, Talbot C, Sen T, Trink B, et al. Phospho-ΔNp63 α is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ. 2011;18(7):1220–30.
161. Cao J-X, Lu Y, Qi J-J, An G-S, Mao Z-B, Jia H-T, et al. MiR-630 inhibits proliferation by targeting CDC7 kinase, but maintains the apoptotic balance by targeting multiple modulators in human lung cancer A549 cells. Cell Death Dis. 2014;5(9):e1426–e1426.
162. Zhang Y, Yu J, Liu H, Ma W, Yan L, Wang J, et al. Novel Epigenetic CREB-miR-630 Signaling Axis Regulates Radiosensitivity in Colorectal Cancer. PLoS One. 2015;10(8):e0133870.
163. Wang Y-W, Chen X, Ma R, Gao P. Understanding the CREB1-miRNA feedback loop in human malignancies. Tumor Biol. 2016;37(7):8487–502.
164. Shi Y, Venkataraman SL, Dodson GE, Mabb AM, LeBlanc S, Tibbetts RS. Direct regulation of CREB transcriptional activity by ATM in response to genotoxic stress. Proc Natl Acad Sci. 2004;101(16):5898–903.
165. Martin NT, Nakamura K, Davies R, Nahas SA, Brown C, Tunuguntla R, et al. ATM–Dependent MiR-335 Targets CtIP and Modulates the DNA Damage Response. PLoS Genet. 2013;9(5):e1003505.
166. Tripathi K, Mani C, Clark DW, Palle K. Rad18 is required for functional interactions between FANCD2, BRCA2, and Rad51 to repair DNA topoisomerase 1-poisons induced lesions and promote fork recovery. Oncotarget. 2016;7(11):12537–53.
167. Deriano L, Roth DB. Modernizing the Nonhomologous End-Joining Repertoire: Alternative and Classical NHEJ Share the Stage. Annu Rev Genet. 2013;47(1):433–55.
168. Jasin M, Rothstein R. Repair of Strand Breaks by Homologous Recombination. Cold Spring Harb Perspect Biol. 2013;5(11):a012740.
169. Meschini R, Berni A, Marotta E, Filippi S, Fiore M, Mancinelli P, et al. DNA Repair Mechanisms Involved in the Removal of DBPDE-Induced Lesions Leading to Chromosomal Alterations in CHO Cells. Cytogenet Genome Res. 2010;128(1–3):124–30.
170. Niziolek-Kierecka M, Dreij K, Lundstedt S, Stenius U. γH2AX, pChk1, and Wip1 as Potential Markers of Persistent DNA Damage Derived from Dibenzo[a,l]pyrene and PAH-Containing Extracts from Contaminated Soils. Chem Res Toxicol. 2012;25(4):862–72.
171. Stellas D, Souliotis VL, Bekyrou M, Smirlis D, Kirsch-Volders M, Degrassi F, et al. Benzo[a]pyrene-induced cell cycle arrest in HepG2 cells is associated with delayed induction of mitotic instability. Mutat Res Mol Mech Mutagen. 2014;769:59–68.
173. Black KA, McFarland RD, Grisham JW, Smith GJ. S-phase block and cell death in human lymphoblasts exposed to benzo[a]pyrene diol epoxide or N-acetoxy-2-acetylaminofluorene. Toxicol Appl Pharmacol. 1989;97(3):463–72.
174. Jeffy BD, Chen EJ, Gudas JM, Romagnolo DF. Disruption of Cell Cycle Kinetics by Benzo[a]pyrene: Inverse Expression Patterns of BRCA-1 and p53 in MCF-7 Cells Arrested in S and G2. Neoplasia N Y N. 2000;2(5):460–70.
175. Solhaug A, Refsnes M, Låg M, Schwarze PE, Husøy T, Holme JA. Polycyclic aromatic hydrocarbons induce both apoptotic and anti-apoptotic signals in Hepa1c1c7 cells. Carcinogenesis. 2004;25(5):809–19.
176. Dansen TB, Burgering BM. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol. 2008;18(9):421–9.
177. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49(11):1603–16.
178. Akyüz M, Ata S. Determination of aromatic amines in hair dye and henna samples by ion-pair extraction and gas chromatography-mass spectrometry. J Pharm Biomed Anal. 2008;47(1):68–80.
179. Ledda C, Loreto C, Zammit C, Marconi A, Fago L, Matera S, et al. Non‑infective occupational risk factors for hepatocellular carcinoma: A review (Review). Mol Med Rep. 2017;15(2):511–33.
180. Banerjee R, Caruccio L, Zhang YJ, McKercher S, Santella RM. Effects of carcinogen-induced transcription factors on the activation of hepatitis B virus expression in human hepatoblastoma HepG2 cells and its implication on hepatocellular carcinomas. Hepatol Baltim Md. 2000;32(2):367–74.
181. Jiangning C, Hongxia Y, Ying L, Wei J, Jie J, Junfeng Z, et al. Ecotoxicological evaluation of 4-aminobiphenyl using a test battery. Ecotoxicol Environ Saf. 2004;58(1):104–9.
182. Saletta F, Matullo G, Manuguerra M, Arena S, Bardelli A, Vineis P. Exposure to the Tobacco Smoke Constituent 4-Aminobiphenyl Induces Chromosomal Instability in Human Cancer Cells. Cancer Res. 2007;67(15):7088–94.
183. Wang S, Sugamori KS, Brenneman D, Hsu I, Calce A, Grant DM. Influence of arylamine n-acetyltransferase, sex, and age on 4-aminobiphenyl-induced in vivo mutant frequencies and spectra in mouse liver. Environ Mol Mutagen. 2012;53(5):350–7.
184. Siriwardhana N, Wang H-CR. Precancerous carcinogenesis of human breast epithelial cells by chronic exposure to benzo[a]pyrene. Mol Carcinog. 2008;47(5):338–48.
185. Li L, Zhao G-D, Shi Z, Qi L-L, Zhou L-Y, Fu Z-X. The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC (Review). Oncol Lett. 2016;12(5):3045–50.
186. Parsons BL, Beland FA, Von Tungeln LS, Delongchamp RR, Fu PP, Heflich RH. Levels of 4‐aminobiphenyl‐induced somatic H‐ras mutation in mouse liver DNA correlate with potential for liver tumor development. Mol Carcinog Publ Coop Univ Tex MD Anderson Cancer Cent. 2005;42(4):193–201.
187. Stanton MF. Diethylnitrosamine-induced hepatic degeneration and neoplasia in the aquarium fish, Brachydanio rerio. J Natl Cancer Inst. 1965;34(1):117–30.
188. Laale HW. Ethanol induced notochord and spinal cord duplications in the embryo of the zebrafish, Brachydanio rerio. J Exp Zool. 1971;177(1):51–64.
189. Rennekamp AJ, Peterson RT. 15 years of zebrafish chemical screening. Curr Opin Chem Biol. 2015;24:58–70.
190. Goldstone JV, McArthur AG, Kubota A, Zanette J, Parente T, Jönsson ME, et al. Identification and developmental expression of the full complement of Cytochrome P450 genes in Zebrafish. BMC Genomics. 2010;11(1):643.
191. Scornaienchi ML, Thornton C, Willett KL, Wilson JY. Functional differences in the cytochrome P450 1 family enzymes from zebrafish (Danio rerio) using heterologously expressed proteins. Arch Biochem Biophys. 2010;502(1):17–22.
192. de Souza Anselmo C, Sardela VF, de Sousa VP, Pereira HMG. Zebrafish (Danio rerio): A valuable tool for predicting the metabolism of xenobiotics in humans? Comp Biochem Physiol Part C Toxicol Pharmacol. 2018;212:34–46.
193. Nakayama J, Gong Z. Transgenic zebrafish for modeling hepatocellular carcinoma. MedComm. 2020;1(2):140–56.
194. Berghmans S, Murphey RD, Wienholds E, Neuberg D, Kutok JL, Fletcher CDM, et al. tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci. 2005;102(2):407–12.
195. Lu J-W, Yang W-Y, Tsai S-M, Lin Y-M, Chang P-H, Chen J-R, et al. Liver-Specific Expressions of HBx and src in the p53 Mutant Trigger Hepatocarcinogenesis in Zebrafish. PLoS One. 2013 Oct 9;8(10):e76951.
196. Lam SH, Wu YL, Vega VB, Miller LD, Spitsbergen J, Tong Y, et al. Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol. 2006;24(1):73–5. |